Comparison · NCT00141453-e55496df
Olmesartan Medoxomil vs Placebo Comparator: Number of Participants Experiencing Cardiovascular Composite Outcomes
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olmesartan Medoxomil vs Placebo Comparator: Number of Participants Experiencing Cardiovascular Composite Outcomes. Trial comparisons, record NCT00141453-e55496df. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00141453-e55496df
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.142 | 0.106 | 0.187 | wilson | |
| Risk in group 2 | 0.187 | 0.146 | 0.236 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0448 | -0.106 | 0.0165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.76 | 0.522 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.72 | 0.46 | 1.13 | log | |
| Number needed to treat, for one fewer participant with the outcome on Olmesartan Medoxomil than on Placebo Comparator | 22.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olmesartan Medoxomil | Experimental: Olmesartan medoxomil tablets 10mg to 40 mg | 40 | 282 | OG000 |
| Group 2 | Placebo Comparator | Matching placebo tablets | 53 | 284 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Experiencing Cardiovascular Composite Outcomes
- Description
Number of participants experiencing the first occurence of any of the following: Cardiovascular death; non-fatal stroke; non-fatal myocardial infarction; hospitalization for unstable angina; lower extremity amputation; coronary/carotid/peripheral revascularization.
- Time frame
- Within 5 years
- Population
- Full analysis set=566
Source ClinicalTrials.gov
Trial
- Title
- ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
- NCT number
- NCT00141453
- Phases
- PHASE3
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Interventions
- olmesartan medoxomil, Placebo Tablets
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Results first posted
- 2011-05-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00141453?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00141453-e55496df